Associate Director for Training and Education
Director, Program in Molecular Medicine, GPILS Associate Director of Training and Education, Marlene and Stewart Greenebaum Cancer Center Associate Director of Basic Research, Center for Vascular and Inflammatory Diseases
800 West Baltimore St. UMB Biopark Building 1, Rm 220
Education and Training
- Rice University, PhD, Biochemistry
- Baylor College of Medicine, Postdoctoral Training, Cell Biology
I completed my doctorate in Biochemistry at Rice University and postdoctoral training in cell biology at Baylor College of Medicine, Houston Texas. I began my research into serine protease inhibitors and the plasminogen activation system when I took a position at a biotechnology company in Sydney Australia. In 1988, I joined the Oncology Program at the Queensland Institute of Medical Research, in Brisbane Australia where my interest in membrane anchored serine proteases evolved. I returned to the United States in 2001 to join the Vascular Biology research program at the Holland Laboratory of the American Red Cross in Rockville Maryland.
In 2004, I joined the faculty of the University of Maryland, School of Medicine as Professor of Physiology and Associate Director of the Center for Vascular and Inflammatory Diseases. My research laboratory is supported by the National Institutes of Health, the Department of Defense, and a Merit Award from the Biomedical Research and Development Service of the Veterans Administration, and I have received past support from the Lance Armstrong Foundation, the Mary Kay Ash Foundation and the Rivkin Foundation for Ovarian Cancer.
I am past president of the American Society for Biochemistry and Molecular Biology (ASBMB), and previously served as president from 2020-2022. I have previously served as Treasurer and Chair of the Publications Committee for the ASBMB. I am active in post-graduate training as the Director of the Molecular Medicine Program in the Graduate Program in Life Sciences (GPILS). I co-direct the T32 Training Program in Cancer Biology supported by the National Cancer Institute and a co-principal investigator on our Post-Baccalaureate Research Education Program (STAR-PREP) supported by NIGMS, NIH. I am a member of the Executive Committee of the Cancer Biology Training Consortium (CABTRAC) and have also served as past President of CABTRAC.
I am a member of the Hormone Responsive Cancers Research Program at the the Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) and serve as Associate Director of Training and Education in support of the broad range of pipeline training programs supported by the UMGCCC. I also serve as a member of the Research and Development Committee Biomedical Research and Development Service of the Veterans Administration at the Baltimore VA.
thrombosis, ovarian cancer, fibrinolysis, coagulation, membrane serine protease, protease-activated receptor, PAR
Duru N, Pawar NR, Martin EW, Buzza MS, Conway GD, Lapidus RG, Liu S, Reader J, Rao GG, Roque DM, Leppla SH, Antalis TM. Selective targeting of metastatic ovarian cancer using an engineered anthrax prodrug activated by membrane-anchored serine proteases. Proc Natl Acad Sci U S A. 2022. PMID: 35867758; PMCID: PMC9282395.
Peroutka RJ, Buzza MS, Mukhopadhyay S, Johnson TA, Driesbaugh KH, Antalis TM. Testisin/Prss21 deficiency causes increased vascular permeability and a hemorrhagic phenotype during luteal angiogenesis. PLoS One. 2020;15(6):e0234407. PMID: 32511276; PMCID: PMC7279603.
Mukhopadhyay S, Gabre J, Chabasse C, Bromberg JS, Antalis TM, Sarkar R. Depletion of CD4 and CD8 Positive T Cells Impairs Venous Thrombus Resolution in Mice. Int J Mol Sci. 2020 Feb 28;21(5):1650. PMID: 32121269; PMCID: PMC7084232.
Mukhopadhyay S, Johnson TA, Duru N, Buzza MS, Pawar NR, Sarkar R, Antalis TM. Fibrinolysis and Inflammation in Venous Thrombus Resolution. Front Immunol. 2019;10:1348. PMID: 31258531; PMCID: PMC6587539.
Conway GD, Buzza MS, Martin EW, Duru N, Johnson TA, Peroutka RJ, Pawar NR, Antalis TM. PRSS21/testisin inhibits ovarian tumor metastasis and antagonizes proangiogenic angiopoietins ANG2 and ANGPTL4. J Mol Med (Berl). 2019 ;97(5):691-709. PMID: 30911775; PMCID: PMC6513752.
Pawar NR, Buzza MS, Antalis TM. Membrane-Anchored Serine Proteases and Protease-Activated Receptor-2-Mediated Signaling: Co-Conspirators in Cancer Progression. Cancer Res. 2019 Jan 15;79(2):301-310. PMID: 30610085; PMCID: PMC6335149.
Mukhopadhyay S, Johnson TA, Sarkar R, Antalis TM. Serpins in Venous Thrombosis and Venous Thrombus Resolution. Methods Mol Biol. 2018;1826:197-211. PMID: 30194602; PMCID: PMC6400456.
Kessler MD, Pawar NR, Martin SS, Antalis TM, O'Connor TD. Improving Cancer Detection and Treatment with Liquid Biopsies and ptDNA. Trends Cancer. 2018 Sep;4(9):643-654. PMID: 30149882; PMCID: PMC6116552.
Buzza, M.S., Johnson, T.A., Conway, G.D., Martin, E.W., Mukhopadhyay, S., Shea-Donohue, T., Antalis, T.M. Inflammatory cytokines down-regulate the barrier-protective prostasin-matriptase proteolytic cascade early in experimental colitis. J Biol Chem. 2017;292(26):10801-10812. PMID: 28490634; PMCID: PMC5491767.
Mukhopadhyay, S., Antalis, T.M., Nguyen, K.P., Hoofnagle, M.H., Sarkar, R. Myeloid p53 regulates macrophage polarization and venous thrombus resolution by inflammatory vascular remodeling in mice. Blood. 2017 Jun 15;129(24):3245-3255. Epub 2017 Mar 20. PMID: 28320710 PMC5472897.
Antalis, T.M. Coagulation signaling to epithelia. Blood. 2016 Jun 23;127(25):3114-6. PMID: 27340252 PMC4920017.
Antalis, T.M., Conway, G.D., Peroutka, R.J., Buzza, M.S. Membrane-anchored proteases in endothelial cell biology. Curr Opin Hematol. 2016 May;23(3):243-52. PMCID: PMC4882107.
Welch, D.R., Antalis, T.M., Burnstein, K., Vona-Davis, L., Jensen, R.A., Nakshatri, H., Riegel, A.T., Spitz, D.R., Watson, D.K., Weiner, G.J. Cancer Biology Training Consortium. Essential Components of Cancer Education. Cancer Res. 2015 Dec 15;75(24):5202-5. Review. PMCID: PMC4681646.
Manton, K.J., Douglas, M.L., Netzel-Arnett, S., Fitzpatrick, D.R., Nicol, D.L., Boyd, A.W., Clements, J.A., Antalis, T.M. Hypermethylation of the 5' CpG island of the gene encoding the serine protease Testisin promotes its loss in testicular tumorigenesis. Br J Cancer. 2015 Dec 1;113(11):1640. PMCID: PMC4705893.
Martin, E.W., Buzza, M.S., Driesbaugh, K.H., Liu, S., Fortenberry, Y.M., Leppla, S.H., Antalis, T.M. Targeting the membrane-anchored serine protease testisin with a novel engineered anthrax toxin prodrug to kill tumor cells and reduce tumor burden. Oncotarget. 2015 Oct 20;6(32):33534-53. PMCID: PMC4741784.
Driesbaugh, K.H., Buzza, M.S., Martin, E.W., Conway, G.D., Kao, J.P., Antalis, T.M. Proteolytic activation of the protease-activated receptor (PAR)-2 by the glycosylphosphatidylinositol-anchored serine protease testisin. J Biol Chem. 2015 Feb 6;290(6):3529-41. PMCID: PMC4319020.
Siefert, S.A., Chabasse, C., Mukhopadhyay, S., Hoofnagle, M.H., Strickland, D.K., Sarkar, R., Antalis, T.M. Enhanced Venous Thrombus Resolution in Plasminogen Activator Inhibitor Type-2 Deficient Mice. J Thromb Haemost. 2014 Jul 10. PMCID: PMC4194171
Shea-Donohue, T., Zhao, A., Antalis, T.M. SerpinB2 mediated regulation of macrophage function during enteric infection.Gut Microbes. 2014 Mar 1;5(2):254-8. PMCID: PMC4063854.
Alaish, S.M., Timmons, J., Smith, A., Buzza, M.S., Murphy, E., Zhao, A., Sun, Y., Turner, D.J., Shea-Donahue, T., Antalis, T.M., Cross, A., Dorsey, S.G. Candidate genes for limiting Cholestatic intestinal injury identified by gene expression profiling. Physiol Rep. 2013 Sep;1(4). doi: 10.1002/phy2.73. PMCID: PMC3808870.
Book Chapter: Bradley, S.G., Antalis, T.M., Bond, J.S.. Chapter 11: Proteases in the Mammalian Digestive System In: K. Brix and W. Stöcker (eds.), Proteases: Structure and Function, Springer-Verlag Wien 2013 DOI 10.1007/978-3-7091-0885-7_11.
Buzza, M.S., Martin, E.W., Driesbaugh, K.H., Désilets, A., Leduc, R., Antalis, T.M. (2013) Prostasin is required for matriptase activation in intestinal epithelial cells to regulate closure of the paracellular pathway. J Biol Chem. Apr 12;288(15):10328-37. PMCID: PMC3624416.
Udofa, E.A., Stringer, B.W., Gade, P., Mahony, D., Buzza, M.S., Kalvakolanu, D.V., Antalis, T.M. (2013) The transcription factor C/EBP-β mediates constitutive and LPS-inducible transcription of murine SerpinB2. PLoS One. 8(3):e57855. PMCID: PMC3589482.
Zhao, A., Yang, Z, Sun, R., Grinchuk, V., Netzel-Arnett, S., Anglin, I.E., Driesbaugh, K.H., Notari, L., Bohl, J.A., Madden, K.B., Urban, J.F. Jr., Antalis, T.M., Shea-Donohue, T. (2013) SerpinB2 is critical to Th2 immunity against enteric nematode infection. J Immunol. Jun 1;190(11):5779-87. PMID: 23630350.
Udofa, E.A., Stringer, B.W., Gade, P., Mahony, D., Buzza, M.S. Kalvakolanu, D.V., Antalis, T.M. The transcription factor C/EBP-β mediates constitutive and LPS-inducible transcription of murine SerpinB2. PLoS One, 8(3): Epub 2013 Mar 5. PMCID: PMC3589482.
Stringer, B., Udofa, E.A., Antalis, T.M. Regulation of the human plasminogen activator inhibitor type 2 gene: cooperation of an upstream silencer and transactivator. J Biol Chem. 2012 Mar 23;287(13):10579-89. PMCID: PMC3322994.
Netzel-Arnett, S., Buzza, M.S., Shea-Donohue, T., Désilets, A., Leduc, R., Fasano, A., Bugge, T.H., Antalis, T.M. Matriptase protects against experimental colitis and promotes intestinal barrier recovery. Inflamm Bowel Dis. 2012 Jul;18(7):1303-14. PMCID: PMC3288858.
Strickland, D.K., Muratoglu, S.C., Antalis, T.M. Serpin-Enzyme Receptors LDL Receptor-Related Protein 1. Methods Enzymol. 2011; 499:17-31. PMCID: PMC3189627.
Antalis, T.M., Bugge, T.H., Wu, Q. Membrane-anchored serine proteases in health and disease. Prog Mol Biol Transl Sci. 2011;99:1-50.
Antalis, T.M., Buzza, M., Hodge, K., Hooper, J.D., Netzel-Arnett, S. Cutting Edge: Membrane anchored Serine Protease Activites in the Pericellular Environment. Biochemical Journal, 2010; 428:325-46.
Cao, C., Gao, Y., Li, Y., Antalis, T.M., Castellino, F.J., Zhang, L. The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. J Clin Invest. 2010 Jun 1;120(6):1971-80. PMCID: PMC2877939
Chen, Y.W., Lee, M.S., Lucht, A., Chou, F.P., Huang, W., Havighurst, T.C., Kim, K., Wang, J.K., Antalis, T.M., Johnson, M.D., Lin, C.Y. TMPRSS2, a serine protease expressed in the prostate on the apical surface of luminal epithelial cells and released into semen in prostasomes, is misregulated in prostate cancer cells. Am J Pathol. 2010 Jun;176(6):2986-96. PMCID: PMC2877858
Buzza, M.S., Netzel-Arnett, S., Shea-Donohue, T., Zhao, A., Lin, C.Y., List, K., Szabo, R., Fasano, A., Bugge, T.H., Antalis, T.M. Membrane-anchored serine protease matriptase regulates epithelial barrier formation and permeability in the intestine. Proc Natl Acad Sci U S A. 2010 107(9):4200-5. PMCID: PMC2840089
Nhu, Q.M., Shirey, K., Teijaro, J.R., Farber, D.L., Netzel-Arnett, S., Antalis, T.M., Fasano, A., Vogel, S.N. Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivo. Mucosal Immunol. 2010; 3(1):29-39. PMCID: PMC2851245
Tripathi, A., Lammers, K.M., Goldblum, S., Shea-Donohue, T., Netzel-Arnett, S., Buzza, M.S., Antalis, T.M., Vogel, S.N., Zhao, A., Yang, S., Arrietta, M-C., Meddings, J.B., Fasano, A. Identification of Human Zonulin, a Physiologic Modulator of Tight Junctions, as Pre-Haptoglobin-2. 2009; Proc Natl. Acad. 106(39):16799-804. PMCID: PMC2744629
Bugge, T.H., Antalis, T.M., Wu, Q. Type II Transmembrane Serine Proteases. J. Biol Chem 2009; 284: 23177-81. PMCID: PMC2749090
Netzel-Arnett, S., Bugge, T.H., Hess, R.A., Carnes, K., Stringer, B.W., Scarman, A.L., Hooper, J.D., Tonks, I.D., Kay, G.F., and Antalis, T.M. The glycosylphosphatidylinositol (GPI)-anchored serine protease Testisin imparts epididymal sperm cell maturation and fertilizing ability. Biol of Reprod. 2009; 81(5):921-32. PMCID: PMC2770021
Antalis, T.M., Bugge, T.H. Methods in molecular biology. Proteases and cancer. Methods and protocols. Preface. Methods Mol Biol. 2009;539:v-vii.
Tonnetti L., Netzel-Arnett, S., Darnell, G., Hayes, T., Buzza, M.S., Anglin, I.E., Suhrbier, A. and Antalis, T. SerpinB2 protection of retinoblastoma protein from calpain enhances tumor cell survival. Cancer Research 68 (14): 2008 Jul 15;68(14):5648-57. PMCID: PMC2561898
Lammers, K.M., Lu, R., Brownley, J., Lu, B., Gerard, C., Thomas, K. Rallabhandi, P., Shea-Donohue, T., Tamiz, A., Alkan, S., Netzel-Arnett, S., Antalis T.M., Vogel, S.N., Fasano, A. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology. 2008, 135(1): 194-204. PMCID: PMC2653457
Darnell, G.A., Schroder, W.A., Antalis, T.M., Lambley, E., Major, L., Gardner, J., Birrell, G., Cid-Arregui, A., Suhrbier, A. Human papillomavirus E7 requires the protease calpain to degrade the retinoblastoma protein. J Biol Chem. 2007, 282 (52): 37492-500.
Antalis, T.M., Shea-Donohue, T., Vogel, S.N., Sears, C., Fasano, A. Mechanisms of disease: protease functions in intestinal mucosal pathobiology. Nat Clin Pract Gastroenterol Hepatol. 2007 Jul;4(7):393-402. Review. PMCID: PMC3049113
Netzel-Arnett, S., Currie, B.M., Szabo, R., Lin, C.Y., Chen, L.M., Chai, K.X., Antalis, T.M., Bugge, T.H., List, K. Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation. J Biol Chem. 2006,281:32941-5.
Darnell, G.A., Schroder, W.A., Gardner, J., Harrich, D., Yu, H., Medcalf, R.L., Warrilow, D., Antalis, T.M., Sonza, S., and Suhrbier, A. (2006) Serpinb2 is an inducible host factor involved in enhancing HIV-1 transcription and replication. J Biol Chem. 281(42):31348-58.
Szabo, R., Netzel-Arnett, S., Hobson, J.P., Antalis, T.M., and Bugge, T.H. (2005) Matriptase-3 is a novel phylogenetically preserved membrane-anchored serine protease with broad serpin reactivity. Biochem J. 390:231-42.
Darnell, G.A., Antalis, T.M., Rose, B.R., and Suhrbier, A. (2005) Silencing of integrated human papillomavirus type 18 oncogene transcription in cells expressing SerpinB2. J Virol. 79(7):4246-56.
Manton, K.J., Douglas, M.L., Netzel-Arnett, S., Fitzpatrick, D.R., Nicol, D.L., Boyd, A.W., Clements, J.A., and Antalis, T.M.(2005) Hypermethylation of the 5' CpG island of the gene encoding the serine protease Testisin promotes its loss in testicular tumorigenesis. Br J Cancer. 92(4):760-9.
Hobson, J.P., Netzel-Arnett, S., Szabo, R., Rehault, S.M., Church, F.C., Strickland, D.K., Lawrence, D.A., Antalis, T.M., and Bugge, T.H. (2004) Mouse DESC1 is located within a cluster of seven DESC1-like genes and encodes a type II transmembrane serine protease that forms serpin inhibitory complexes. J Biol Chem. 279(45):46981-94.
Darnell, G.A., Antalis, T.M., Johnstone, R.W., Stringer, B.W., Ogbourne, S.M., Harrich, D., and Suhrbier A. (2003) Inhibition of Retinoblastoma Protein Degradation by Interaction with the Serpin Plasminogen Activator Inhibitor 2 via a Novel Consensus Motif. Mol Cell Biol. 23(18):6520-6532.
Netzel-Arnett, S, Hooper, J.D., Szabo, R., Madison, E.L., Quigley, J.P., Bugge, T.H. and Antalis, T.M. (2003) Membrane Associated Serine Proteases: A rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer and Metastasis Reviews. 22:237-258.
Aimes, R.T., Zijlstra, A., Hooper, J.D., Ogbourne, S., Sit, M.-L., Fuchs, S., Gotley, D.C., Quigley, J.P., and Antalis, T.M.(2003) Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis. Thrombosis and Haemostasis. 89(3):561-572.
Hooper, J.D., Clements, J.A., Quigley, J.P., and Antalis, T.M. (2000) Type II Transmembrane Serine Proteases - Insights into an emerging class of cell surface proteolytic enzymes. Mini Review, J Biol Chem. 276(2), 857-860.
Hooper, J.D., Scarman, A.L., Clarke, B., Normyle, J.F., and Antalis, T.M. (2000) The mosaic transmembrane serine protease corin is expressed in heart myocytes. Eur. J. Biochem. 267(23), 6931-6937.
Hooper, J.D., Nicol, D.L., Dickinson, J.L., Eyre, H.J., Scarman, A.L., Normyle, J.F., Stuttgen, M.A., Douglas, M., Loveland, K.A.L., Sutherland, G.R., and Antalis, T.M. (1999) Testisin, a new human serine protease expressed by premeiotic testicular germ cells and lost in testicular germ cell tumors. Cancer Research. 59(13): 3199-31205.
Antalis, T.M., Lin, M.L., Donnan, K., Mateo, L., Gardner, J., Dickinson, J.L., Buttigieg, K., and Suhrbier, A. (1998) The serpin plasminogen activator inhibitor type 2 (PAI-2) protects against viral cytopathic effects: evidence for a PAI-2 mediated influence on the interferon alpha/beta signaling pathway. J. Exp. Med. 187: 1799-1811.
Antalis TM, Clark MA, Barnes T, Lehrbach PR, Devine PL, Schevzov G, Goss NH, Stephens RW, Tolstoshev P. Cloning and expression of a cDNA coding for a human monocyte-derived plasminogen activator inhibitor. Proc Natl Acad Sci U S A. 1988 Feb;85(4):985-9. PMID: 3257578; PMCID: PMC279685.
Antalis TM, Palmer G. Kinetic characterization of the interaction between cytochrome oxidase and cytochrome c. J Biol Chem. 1982 Jun 10;257(11):6194-206. PMID: 6281261.
Our research is focused on signaling mechanisms involved in vascular disease and cancer. We focus on the biology of serine proteases and their inhibitors (serpins) to determine their potential as targets for diagnostic applications or rational drug-based therapies for various diseases. Proteases are powerful hydrolytic enzymes that mediate cleavage, activation and degradation of many cellular proteins, and therefore play fundamental roles in virtually every aspect of cell behavior, including survival, growth, differentiation, and malignant transformation.
Inappropriate proteolysis can significantly impact disease progression, thus proteases represent attractive targets for therapeutic intervention in a wide range of disorders and diseases. The serine proteases are one of the largest and most highly conserved multigene families. These proteases are distinguished by the fact that a serine residue plays a critical role in the catalytic process. Members of the serine protease family are well recognized to initiate and control complex biological systems, such as blood coagulation, wound healing, digestion, immune responses, reproduction and development.
Recently, through genomics and database mining approaches, the existence of membrane-anchored serine proteases has been recognized. This is a unique group of molecules that contain serine protease domains in addition to multiple other structural domains, and which include hydrophobic membrane-anchoring sequences. We currently know very little about these enzymes and their activities. Disruption or mutation of several of the genes encoding these proteases are directly associated with inherited genetic diseases, and while many of the membrane-anchored serine proteases show restricted tissue distribution in normal cells, their expression is widely dysregulated during tumor growth and progression.
A detailed understanding of these proteases and how they interact with other proteases and cell associated signaling molecules is necessary for our understanding of cell growth and regulation as it relates to cancer, angiogenesis and vascular diseases.
Our current research interests include:
- Physiological roles of membrane anchored serine proteases in cell biology, cancer and angiogenesis. A focus is the function of testisin in angiogenesis, and the contributions of membrane-anchored serine proteases to ovarian cancer malignancy and chemotherapy resistance.
- Mechanisms associated with protease-activated receptor signaling during inflammation and in endothelial and epithelial barrier functions.
- The activity of the plasminogen activation cascade in clot dissolution and particularly the role of the serpin, plasminogen activator inhibitor type-2 (PAI-2), as a key inhibitory target to accelerate venous thrombus resolution and reduce morbidity in patients.
US Patent 5,422,090, June 6, 1995, Human PAI-2. Inventors: R.W. Stephens, J.P.Golder, M. Antalis, T.Barnes, M. Clark, P. Devine, N. Goss, P. Lehrbach. Commercialized by PI2, Pt Ltd., Australia
US Patent 5,426,044, June 20, 1995, Minactivin compositions and antibodies to minactivin. Inventors: M. Antalis, T.Barnes, M. Clark, P. Devine, N. Goss, P. Lehrbach. Commercialized by PI2, Pt Ltd., Australia
US Patent 6,479,274, November 12, 2002, Novel molecules (Discovery of new serine proteases). Inventors: M. Antalis, J. Hooper. Licensed to diaDexus Inc., San Francisco, CA
US. Patent 10,568,929, “Engineered Anthrax Protective Antigen Proteins for Cancer Therapy,” issued on February 25, 2020. Inventors: T.M. Antalis, E Martin.
US. Patent 11,013,784, “Engineered Anthrax Protective Antigen Proteins for Cancer Therapy” issued on May 25, 2021. Inventors: T.M. Antalis, E Martin.
We generate and make extensive use of knockout and transgenic mouse models for determining essential gene functions, as well as incorporate both microarray and proteomics approaches for differential molecular analyses. We also employ a range of mouse models for the study of tumor growth and metastasis, analysis of new blood vessel formation (angiogenesis).
Recombinant DNA techniques, including cloning, mutagenesis and heterologous expression are used routinely and are coupled with state-of-the-art cell biological analyses such as confocal fluorescence microscopy. We produce recombinant proteases for analyses of their biochemical and enzymatic properties.
We also utilize molecular approaches such as immunoblotting, immunoprecipitation, reporter gene assays, and microarray techniques to study cellular signaling pathways involved in cell growth/death regulation and differentiation.
UMGCCC Cancer research Career Enhancement and Related Activities: https://www.umms.org/umgccc/healthcare-professionals/crcera
- Marguerite Buzza, PhD, (C. J. Martin Fellow, Australia); Research Associate
- Nadire Duru, PhD, Research Associate
- Subhradip Mukhopadhyay, PhD, Research Associate
- Tierra Johnson, Molecular Medicine Graduate Student, GPILS (T32 Trainee)
- Amando Strong, Biochemistry and Molecular Biology Graduate Student, GPILS (T32 Trainee)
- Kathryn Hodge Dreisbaugh, PhD (May 2014)(T32 Trainee
- Ekemini Udofa, PhD (May 2014) (IMSD Scholar)
- Erik Martin, PhD, (May 2015)(T32 Trainee)
- Gregory Conway, PhD (May 2020)
- R.J. Peroutka, PhD (May 2021)
- Nisha Pawar, PhD, (May 2022)(T32 Trainee)